Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Finished Goods (2022 - 2025)

Historic Finished Goods for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $65000.0.

  • BioXcel Therapeutics' Finished Goods fell 9060.69% to $65000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $65000.0, marking a year-over-year decrease of 9060.69%. This contributed to the annual value of $173000.0 for FY2024, which is 5728.4% down from last year.
  • BioXcel Therapeutics' Finished Goods amounted to $65000.0 in Q3 2025, which was down 9060.69% from $73000.0 recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Finished Goods peaked at $1.4 million during Q2 2024, and registered a low of $65000.0 during Q3 2025.
  • In the last 4 years, BioXcel Therapeutics' Finished Goods had a median value of $599500.0 in 2022 and averaged $645000.0.
  • Its Finished Goods has fluctuated over the past 5 years, first skyrocketed by 31433.33% in 2023, then tumbled by 9496.55% in 2025.
  • BioXcel Therapeutics' Finished Goods (Quarter) stood at $595000.0 in 2022, then plummeted by 31.93% to $405000.0 in 2023, then crashed by 57.28% to $173000.0 in 2024, then crashed by 62.43% to $65000.0 in 2025.
  • Its Finished Goods stands at $65000.0 for Q3 2025, versus $73000.0 for Q2 2025 and $178000.0 for Q1 2025.